BEGIN:VCALENDAR
VERSION:2.0
PRODID:talks.ox.ac.uk
BEGIN:VEVENT
SUMMARY:Mapping the behaviour of PIK3CA mutant clones in endothelial cells
  - Dr Mariona Graupera (Josep Carreras Leukaemia Research Institute)
DTSTART;VALUE=DATE-TIME:20260320T150000Z
DTEND;VALUE=DATE-TIME:20260320T160000Z
UID:https://talks.ox.ac.uk/talks/id/f133b630-04ea-4ce1-ad70-eb56ee7c3f26/
DESCRIPTION:The Graupera lab takes advantage of the PI3K pathway as a para
 digm to understand how intracellular signalling pathways regulate vessel m
 orphogenesis\, and how this knowledge can be translated into therapeutic o
 pportunities for diseases characterized by aberrant vessel growth. Our res
 earch has identified key and selective roles of several members of the PI3
 K pathway\, including PI3Ka\, PI3Kb\, PTEN\, and PI3K-C2b (J Exp Med\, Nat
  Commun\, Clin Cancer Res\, Sci Transl Med\, Circulation\, Nature Metaboli
 sm\, EMBO Mol Med\, Sci Sig). Over the last decade\, PI3Kα/PIK3CA has bee
 n recognised as a master regulator of EC biology. M Graupera has dedicated
  more than 20 years to studying this isoform in ECs. These discoveries spa
 n from: (1) the selective and cell-autonomous requirement of PI3Ka in deve
 lopmental angiogenesis (Graupera et al. Nature 2008)\; (2) the contributio
 n of PI3Ka in tumour angiogenesis (Soler et al. JEM 2013)\; (3) the unders
 tanding of the primary cell biological function of PI3Ka in angiogenic ECs
  (Angulo-Urarte et al. Nat Commun 2018)\; (4) the discovery that PIK3CA is
  mutated in the embryonic ECs\, leading to venous malformations (Castillo 
 et al. Sci Trasl Med 2016)\; (5) the PIK3CA-dependency to growth factor fo
 r pathogenesis (Kobialka et al. Embo Mol Med 2022). We have published a ve
 ry comprehensive review on PIK3CA mutations in congenital disorders (Angul
 o-Urarte et al. NCVR 2022). Together\, these observations have represented
  a breakthrough in the field\, capitalizing on the repurposing of PI3K for
  these diseases. The Graupera lab works in close collaboration with paedia
 tric clinicians at Hospital Sant Joan de Déu\, Barcelona\, to apply her d
 iscoveries in clinical practice to treat these patients.\n\nAbout Mariona 
 Graupera: I am a vascular biologist with expertise in signalling. I have b
 een trained in several institutions\, including the University of Barcelon
 a\, the Hospital Clinic de Barcelona\, the Ludwig Institute for Cancer Res
 earch\, and the Bart’s Cancer Institute in London. In 2009 I established
  my lab as an independent investigator at d’Investigació Biomèdica de 
 Bellvitge (IDIBELL) funded by the Ramon y Cajal program. In February 2021\
 , I joined the Josep Carreras Leukaemia Research Institute as Group leader
 . In June 2022\, I was elected President of the European Vascular Biology 
 Organization (EVBO)\, and I served as a resident until June 2025. In Janua
 ry 2023\, I was appointed ICREA Research Professor.\nSpeakers:\nDr Mariona
  Graupera (Josep Carreras Leukaemia Research Institute)
LOCATION:IMS-Tetsuya Nakamura Building (IDRM Seminar Rooms 1&2 or via Team
 s link)\, Roosevelt Dr\, Headington OX3 7TY
TZID:Europe/London
URL:https://talks.ox.ac.uk/talks/id/f133b630-04ea-4ce1-ad70-eb56ee7c3f26/
BEGIN:VALARM
ACTION:display
DESCRIPTION:Talk:Mapping the behaviour of PIK3CA mutant clones in endothel
 ial cells - Dr Mariona Graupera (Josep Carreras Leukaemia Research Institu
 te)
TRIGGER:-PT1H
END:VALARM
END:VEVENT
END:VCALENDAR